<p>The value in the different drug columns indicates the average Log FC in the presence of this mutation. While these mutations have been selected to confer some resistance to all NNRTIs, each drug still has a distinct profile. Efavirenz is the most sensitive (average Log FC 0.79) and Etravirine the least (average Log FC 0.44) with Nevirapine (average Log FC 0.55) and Delavirdine (average Log FC 0.58) in between.</p
<p>Histogram showing number of women with drug resistant HIV infection that had each of the followin...
WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and tw...
OBJECTIVE: To compare virological outcome and genotypic resistance profiles in HIV-1-infected patien...
<p>The value in the different drug columns indicates the average Log FC in the presence of this muta...
ObjectivesThe introduction of two new non-nucleoside reverse transcriptase inhibitors (NNRTIs) in th...
<p>HIVDB genotypic resistance interpretation program predictions of NRTI, NNRTI, and PI resistance f...
Objectives: To evaluate whether etravirine (TMC125) might be effective in patients failing therapy w...
An integrated computational and statistical approach was used to determine the association of non-nu...
BACKGROUND: Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI)...
<p>Keys: NNRTIs-efavirenz (EFV), etravirine (ETR), nevirapine (NVP), rilpivirine (RPV); NRTIs-lamuvi...
<p>Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in...
Objectives: To evaluate the expected activity of etravirine in clinical samples, according to mutati...
<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only s...
<p>The mutations that were not detected in either treatment groups are not included. The numbers rep...
Determining the phenotypic impacts of reverse transcriptase (RT) mutations on individual nucleoside ...
<p>Histogram showing number of women with drug resistant HIV infection that had each of the followin...
WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and tw...
OBJECTIVE: To compare virological outcome and genotypic resistance profiles in HIV-1-infected patien...
<p>The value in the different drug columns indicates the average Log FC in the presence of this muta...
ObjectivesThe introduction of two new non-nucleoside reverse transcriptase inhibitors (NNRTIs) in th...
<p>HIVDB genotypic resistance interpretation program predictions of NRTI, NNRTI, and PI resistance f...
Objectives: To evaluate whether etravirine (TMC125) might be effective in patients failing therapy w...
An integrated computational and statistical approach was used to determine the association of non-nu...
BACKGROUND: Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI)...
<p>Keys: NNRTIs-efavirenz (EFV), etravirine (ETR), nevirapine (NVP), rilpivirine (RPV); NRTIs-lamuvi...
<p>Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in...
Objectives: To evaluate the expected activity of etravirine in clinical samples, according to mutati...
<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only s...
<p>The mutations that were not detected in either treatment groups are not included. The numbers rep...
Determining the phenotypic impacts of reverse transcriptase (RT) mutations on individual nucleoside ...
<p>Histogram showing number of women with drug resistant HIV infection that had each of the followin...
WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and tw...
OBJECTIVE: To compare virological outcome and genotypic resistance profiles in HIV-1-infected patien...